---
title: DexCom, Inc. (DXCM)
layout: default
nav_order: 437
---

# DexCom, Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $38.5 B

DexCom develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for people with diabetes.  Their core product is the G6 CGM system.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=DXCM+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/DXCM/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat:**

DexCom earns a 3/5 moat rating due to its strong brand name, switching costs associated with its integrated system (receiver, sensor, transmitter) and data platform, and network effects that stem from data sharing.

* **Brand:** DexCom has built a loyal customer base thanks to the accuracy and reliability of its products. Its brand is associated with quality and innovation in the CGM space. This brand strength enables a degree of pricing power, as evidenced by the fact that DexCom’s products often command premium prices.
* **Switching Costs:** The G6 system requires patients to use specific receivers, sensors, and transmitters, making it inconvenient to switch to another brand of CGM. The company also offers software and a data platform, thus providing patients and healthcare providers with a comprehensive ecosystem. These system integrations create meaningful switching costs and lock-in customers. 
* **Network Effects:** DexCom’s data platform allows users to share data with others, including healthcare providers. This data sharing strengthens the network and makes DexCom’s products more valuable to current and potential users.  The more users share data, the larger the data set becomes, making algorithms more powerful and accurate.


{: .note }

While these characteristics contribute to a moat, it's important to be skeptical about its durability.  The CGM market is evolving rapidly, and new competitors could emerge with superior technology or business models. Abbott Laboratories, for instance, is a significant competitor in the CGM market. Also, innovation can be a double-edged sword; a better, cheaper product can quickly render DexCom's technology obsolete.

**Management:**

DexCom’s management receives a 3/5 rating. While they have overseen significant growth, there are some areas of concern that prevent a higher rating.

* **History & Experience:** The management team has a mixed track record. Kevin Sayer, President, Chief Executive Officer and Chairman of the Board, has been with the company since 2001 and has overseen impressive revenue growth. However, this growth has come at a cost, with profitability lagging.  (Q3 2024 earnings call)
* **Compensation:** Executive compensation appears to be heavily weighted toward stock options. While some level of stock-based compensation is appropriate, excessive reliance on stock options can incentivize short-term decision-making, sometimes at the expense of long-term value creation. (DexCom 2023 10-K)
* **Capital Allocation:** While the company has pursued an aggressive growth strategy, questions remain about the efficiency of their capital allocation. The company’s reinvestment rate has been very high, and its returns on capital have been uneven over the years. For instance, in 2023, the company reported a loss on its non-core investments. (DexCom 2023 10-K)
* **Communication:**  While management provides some key drivers in their financial releases, they could provide a more detailed explanation of their assumptions and reasoning behind capital allocation decisions, such as their substantial share repurchase program. 
* **Insider Ownership:**  Insider ownership is relatively low, giving a signal that insiders may not be as aligned with shareholders as they could be.

{: .important }

Overall, management's focus on growth has led to impressive revenue expansion but uneven profitability and returns on capital.  Their capital allocation decisions and communication with shareholders could be improved.

**Business:**

* **Revenues Distribution:** DexCom generates the vast majority of its revenue from sales of its CGM systems, primarily in the United States. (Q3 2023 earnings call)
* **Industry Trends:** The CGM market is growing rapidly, driven by increasing diabetes prevalence and greater awareness of the benefits of continuous glucose monitoring.  However, competition is also intensifying.
* **Margins:**  While gross margins are relatively high, operating margins are low due to significant spending on research and development, sales, and marketing.
* **Competitive Landscape:**  DexCom faces competition from several larger, more established companies, including Abbott Laboratories.  Maintaining its competitive edge will require ongoing innovation and effective cost control.
* **Differentiating Factors:** DexCom's products are known for their accuracy and ease of use. The company also benefits from its integrated system and data platform.


**Financials:**

DexCom's financials reveal a company experiencing rapid revenue growth but struggling with profitability. Over the last three years (2021-2023), revenues have nearly tripled, but the company is still not consistently generating profits.  (DexCom, Inc. 10-K filings 2021-2023).  The company's heavy reinvestment in research and development, and sales and marketing has pressured margins. (Q3 2023 earnings call)

**Valuation:**

A two-stage discounted cash flow (DCF) model is used to estimate DexCom's intrinsic value. A pessimistic outlook is taken, reflecting the competitive intensity of the industry and the company’s uneven track record on profitability.

* **Stage 1 (2024-2029):**
    * Revenue Growth: 8% (declining to 6% by year 6) - Based on historical growth and industry forecasts, tempered by a pessimistic outlook given the competitive landscape.  
    * Operating Margin: 12% (rising to 14% by year 6) -  Assumes some margin improvement as the company scales but remains below its competitors’ margins given the competitive intensity.
    * Reinvestment Rate: 25% - Reflects the need for ongoing investment to maintain competitive advantage, again taking a pessimistic view.
    * Cost of Capital: 9% -  Derived using a risk-free rate of 4.1%, an equity risk premium of 4.5%, a beta of 1.34 (based on comparable companies), and a target capital structure of 75% equity and 25% debt.
    * Terminal Growth: 3% - A conservative assumption given the long-term growth rate of the U.S. economy.
* **Stage 2 (2030-Perpetuity):**  Assumes a stable growth rate of 3% and a ROIC of 10% - Reflecting a mature company with limited growth but stable returns.

**Calculations:**

* Based on these inputs, the present value of free cash flow to the firm is $31,230 million for Stage 1 and $7,299 million for Stage 2 using the growing perpetuity formula.  (Koller, Goedhart, and Wessels, *Valuation*)
* Adding the present value of cash and subtracting debt yields a total value of the firm of $38,529 million. 
* Dividing this by the shares outstanding yields an intrinsic value per share of $101.50, compared with a trading price at the time of this valuation of $114.

{: .warning }

The DCF model is highly sensitive to the input assumptions, and small changes in long-term growth or margin can significantly affect the estimated value. Given the competitive intensity of the CGM space, unforeseen competitive pressures could lead to a drastically lower value than anticipated.

**Catalysts:**

DexCom earns a 2/5 catalyst rating. 

* **Product innovation:** DexCom is constantly innovating and introducing new products and product extensions. The launch of a new product that can reach new patients or a product that can reach new markets or a product that is demonstrably better than the products offered by the competitors (Abbott, Medtronic and Senseonics), would be a game-changer for DexCom.
* **Expansion into new markets:**  DexCom is expanding into new geographic markets, which could drive revenue growth. (Q1 2024 earnings call)  
* **Partnerships:** Strategic partnerships with other healthcare companies could help DexCom expand its reach and accelerate growth.  


{: .warning }

Although these are potential catalysts, the probability of substantial success is uncertain given that markets tend to incorporate positive expectations into today’s prices. Moreover, the CGM market remains highly volatile, and a catalyst can be cancelled by a broader market downturn.

**Recent Concerns and Controversies:**

In a 2024 earnings call, Kevin Sayer addressed recent concerns about intensifying competition from Abbott Laboratories:  "We do expect Abbott to be very formidable competitors over the long haul. They clearly have a very good sensor." He went on to emphasize DexCom's continued focus on innovation and product development. This acknowledges the challenging competitive landscape and affirms the importance of sustaining the company's innovative edge to maintain its moat.